Back to search results

Cannabis Withdrawal in Hospitalized Cancer Patients Undergoing BMT or CAR-T Therapy

This study is looking at how common cannabis withdrawal is and what it looks like in adult patients hospitalized for a bone marrow transplant (BMT) or CAR T-cell therapy (a type of immunotherapy that uses your own modified immune cells to fight cancer). You might be able to join if you are an adult admitted for BMT or CAR-T therapy and can give informed consent. The researchers want to understand the prevalence (how often it happens) of cannabis withdrawal and how severe the symptoms are. This information will be gathered for up to one year, with daily symptom checks for the first four days of hospitalization. The study is currently unclear on its recruitment status.

Study design
This is an observational study, meaning researchers will watch and collect information without giving any specific treatments. It plans to include about 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track the prevalence of cannabis withdrawal for up to one year and the severity of withdrawal symptoms daily for the first four days of hospitalization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594496

Prevalence and Clinical Manifestations of Cannabis Withdrawal in Hospitalized Patients With Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) or Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Enrolling by Invitation
Not specifiedAges 18+Observational
Mayo Clinic
~300 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of cannabis withdrawal
Measured over Up to 1 year
+1 more outcome measured

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

NCT07594496

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Arizona

    Scottsdale, Arizonano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Osama A. Abulseoud, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Sondra Schultz, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All adult patients admitted for BMT or CAR-T therapy

Exclusion

Individuals unable to provide informed consent

What this trial measures

  • Prevalence of cannabis withdrawalUp to 1 year

    Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.

  • Severity of withdrawal symptomsDaily for first 4 days of hospitalization

    Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.